6-氯-5-硝基烟酸甲酯 | 59237-53-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-5-硝基烟酸甲酯
• 中文别名: 6-氯-5-硝基-3-吡啶羧酸甲酯；5-硝基-6-氯烟酸甲酯
• 英文名称: methyl 6-chloro-5-nitro-pyridine-3-carboxylate
• 英文别名: methyl 6-chloro-5-nitronicotinate；6-chloro-5-nitronicotinic acid methyl ester；methyl 2-chloro-3-nitropyridine-5-carboxylate；methyl 6-chloro-5-nitropyridine-3-carboxylate
• CAS: 59237-53-5
• 化学式: C₇H₅ClN₂O₄
• 分子量: 216.581
• InChiKey: BRPREIDVQXJOJH-UHFFFAOYSA-N

物化性质

• 熔点：
  76 °C
• 沸点：
  317.8±37.0 °C(Predicted)
• 密度：
  1.500±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  85
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 6-chloro-5-nitronicotinate
Synonyms: Methyl 2-chloro-3-nitro-5-pyridinecarboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 6-chloro-5-nitronicotinate
CAS number: 59237-53-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN2O4
Molecular weight: 216.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯-5-硝基烟酸甲酯 在 盐酸 、 sodium sulfide nonahydrate 、 硫化氢 、 sodium acetate 、 sodium sulfate 、 锌 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 溶剂黄146 为溶剂， 生成 5-氨基-6-硫氧代-1,6-二氢吡啶-3-羧酸甲酯
  参考文献：
  名称：

  Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity

  摘要：

  氨基哌啶衍生物的公式(I)及其药物可接受的衍生物，用于治疗哺乳动物，特别是人类的细菌感染。

  公开号：

  US20040038998A1
• 作为产物：
  描述：

  2-羟基-3-硝基吡啶-5-羧酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 6-氯-5-硝基烟酸甲酯
  参考文献：
  名称：

  Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype

  摘要：

  DOI：

  10.1016/j.bmcl.2021.128376
• 作为试剂：
  描述：

  3-bromo-7-chloro-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indole 、 三丁基(1-乙氧基乙烯)锡 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 、 6-氯-5-硝基烟酸甲酯 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 16.33h， 以51%的产率得到1-{7-chloro-8-fluoro-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-3-yl}ethan-1-one
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
  [FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX

  摘要：

  本发明涉及三环化合物，包括本发明化合物的药用可接受组合物以及在治疗各种疾病中使用所述组合物的方法。

  公开号：

  WO2016183114A1

文献信息

• 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途
  申请人：中国医学科学院药物研究所

  公开号：CN112279835B

  公开（公告）日：2022-07-22

  本发明涉及一类含芳环或芳杂环并咪唑结构的化合物或其药学上可接受盐，其制备方法，含有该类化合物的药物组合物以及该类化合物的医药用途。本发明化合物具有特异性激动STING蛋白的作用，能够用于制备治疗恶性肿瘤、病毒感染等与STING蛋白功能相关的疾病的药物。
• [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE
  申请人：KANCERA AB

  公开号：WO2017108282A1

  公开（公告）日：2017-06-29

  A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

  化合物的化学式（Ia）或（Ib）或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶的抑制剂，因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。
• [EN] 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE ET DE 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE DE C-MYC ET P300/CBP POUR LE TRAITEMENT DU CANCER
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019049061A1

  公开（公告）日：2019-03-14

  The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity & nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的5-(1H-苯并[d]咪唑-2-基)-吡啶-2-胺和5-(3H-咪唑[4,5-b]吡啶-6-基)-吡啶-2-胺衍生物。具体而言，本发明涉及根据公式(lb)的化合物，其中R'、R2'、R3'、R4'、Rs'、R6'、R7'和X1'按本说明书中定义；或其盐，包括药用可接受的盐。本发明的化合物能够降低细胞中的MYC蛋白（c-MYC）和/或抑制p300/CBP组蛋白乙酰转移酶，可用于治疗心肌肥大、糖尿病、肥胖和非酒精性脂肪肝疾病、HIV、多囊肾疾病、炎症性疾病、强直性脊柱炎、银屑病、银屑病关节炎、类风湿性关节炎、克罗恩病、多发性硬化症、癌症和前癌症综合症，以及与Myc失调或p300/CBP组蛋白乙酰转移酶抑制相关的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步公开了使用本发明的化合物或包含本发明化合物的药物组合物，降低细胞中MYC蛋白（c-MYC）和抑制p300/CBP组蛋白乙酰转移酶活性的方法，以及治疗与之相关的疾病的方法。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2015026792A1

  公开（公告）日：2015-02-26

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists
  作者：Qiumu Xi、Mingjin Wang、Wenqiang Jia、Mingjian Yang、Jinping Hu、Jing Jin、Xiaoguang Chen、Dali Yin、Xiaojian Wang

  DOI：10.1021/acs.jmedchem.9b01567

  日期：2020.1.9

  Stimulator of interferon genes (STING) is an endoplasmic reticulum-localized adaptor protein (STING receptor) that has been shown to be activated by binding to natural cyclic dinucleotide (CDN) ligands and plays a vital role in innate immune sensing of exogenous or endogenous DNA, which then induces type I interferons and other cytokines. In this paper, we described a series of amidobenzimidazole STING

  干扰素基因刺激物（STING）是一种内质网定位的衔接蛋白（STING受体），已被证明可通过与天然环二核苷酸（CDN）配体结合而被激活，并且在外源或内源DNA的固有免疫传感中起着至关重要的作用然后诱导I型干扰素和其他细胞因子。在本文中，我们描述了一系列对STING受体具有高效力的酰胺基苯并咪唑STING激动剂，并提出了相关的构效关系（SAR）。通过STING竞争结合测定法测量化合物16g，24b和24e的相对效力。对STING信号通路影响的更彻底研究表明，三种化合物16g，24b和24e显着增加了IFN-β，CXCL10和IL-6的蛋白质水平和mRNA水平，以及作为代表化合物的24b有效地触发了人类外周血单核细胞（hPBMC）和WT THP-1细胞中STING，TBK1和IRF3的磷酸化。另外，化合物24b在具有确定的同基因结肠肿瘤的小鼠中通过静脉内给药显示出令人印象深刻的抗肿瘤功效。此外，